The leader in advanced diagnostic testing for neurology, endocrinology and nephrology.
Location: United States, Massachusetts, Worcester
Investors 1
| Date | Name | Website |
| - | Behrman Ca... | behrmancap... |
Mentions in press and media 5
| Date | Title | Description |
| 11.03.2024 | Neurological Biomarkers Market 2024 Global Analysis: Insights, Size, Share |Athena Diagnostics, Psynova Neurotech | Neurological Biomarkers Market Neurological biomarkers are detectable substances majorly found in the cerebrospinal (CSF) fluid when there has been some damage to the brain. BURLINGAME, CALIFORNIA , UNITED STATES, March 11, 2024 /EINPresswi... |
| 11.04.2012 | Quest Diagnostics announces new CEO, gets approval for C difficile test | Philips Healthcare is the largest component of Royal Philips Electronics. Under Rusckowski’s tenure, sales in the Healthcare Division rose from $8.6 billion (€6.6 billion) in 2007 to $11.7 billion (€8.9 billion) in 2011. Last year, the comp... |
| 24.01.2012 | Quest Diagnostics seeks to grow its healthcare IT business | In a conference call with analysts, Quest Diagnostics CEO Surya N. Mohapatra said the company’s growth strategy is based on three elements, including driving innovative new tests and advancing healthcare IT services. It also wants to enhanc... |
| - | Quest Diagnostics seeks to grow its healthcare IT business | Diagnostic testing company Quest Diagnostics (NYSE:DGX) is looking to grow its healthcare IT business following an increase in fourth-quarter revenue and profits partly from acquisitions made last year. The Madison, New Jersey lab testing g... |
| - | Quest Diagnostics announces new CEO, gets approval for C difficile test | Quest Diagnostics (NYSE:DGX), one of the largest diagnostic testing providers, has announced a replacement for its outgoing CEO. Dr. Surya N. Mohapatra will be succeeded by Philips Healthcare CEO Steve Rusckowski effective May 1, according ... |